[1]杜 亮,阿布都买拉木·阿布都吾甫尔,金澄宇,等.非小细胞肺癌组织中ADH5 mRNA，FUNDC1 mRNA的表达与临床病理特征及预后的关系研究[J].现代检验医学杂志,2025,40(02):36-40.[doi:10.3969/j.issn.1671-7414.2025.02.007]
　DU Liang,ABUDUMAIRAMU Abudumufur,JIN Chengyu,et al.Relationship between Expression of ADH5 mRNA，FUNDC1 mRNA and Clinicopathological Features and Prognosis in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2025,40(02):36-40.[doi:10.3969/j.issn.1671-7414.2025.02.007]
点击复制

非小细胞肺癌组织中ADH5 mRNA，FUNDC1 mRNA的表达与临床病理特征及预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年02期
页码:
36-40
栏目:
论著
出版日期:
2025-03-15

文章信息/Info

Title:
Relationship between Expression of ADH5 mRNA，FUNDC1 mRNA and Clinicopathological Features and Prognosis in Non-Small Cell Lung Cancer
文章编号:
1671-7414（2025）02-036-05
作者:
杜 亮; 阿布都买拉木·阿布都吾甫尔; 金澄宇; 马金山
（新疆维吾尔自治区人民医院胸外科，乌鲁木齐 830000）
Author(s):
DU Liang; ABUDUMAIRAMU Abudumufur; JIN Chengyu; MA Jinshan
（Department of Thoracic Surgery， People’s Hospital of Xinjiang Uygur Autonomous Region，Urumqi 830000，China）
关键词:
非小细胞肺癌; 乙醇脱氢酶5; FUN14 结构域蛋白 1
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.02.007
文献标志码:
A
摘要:
目的 研究非小细胞肺癌（NSCLC）组织中乙醇脱氢酶5（ADH5）mRNA，FUN14 结构域蛋白 1（FUNDC1）mRNA 的表达与临床病理特征及预后的关系。方法 收集2019 年7 月～ 2021 年7 月在新疆维吾尔自治区人民医院接受治疗并经术后病理确诊为NSCLC 的332 例患者的临床资料。应用实时荧光定量PCR（qRT-PCR）法测定NSCLC 组织及相应的癌旁组织（距癌组织边缘>5cm）中ADH5 mRNA 和FUNDC1 mRNA 的表达情况，并通过t 检验分析其表达差异及其与NSCLC 患者临床病理特征的相关性；采用Pearson 等级相关分析ADH5 mRNA 与FUNDC1 mRNA 的相关性；Kaplan-Meier 法分析ADH5 mRNA 和FUNDC1 mRNA 表达与NSCLC 患者预后的关系。结果 qRT-PCR 结果显示，NSCLC 组织中ADH5 mRNA 表达水平（0.56±0.30）显著低于癌旁正常组织（1.03±0.50），而FUNDC1 mRNA 表达水平（2.91±1.02）显著高于癌旁正常组织（1.20±0.83），差异具有统计学意义（t=14.687，23.694，均P<0.05）；且Pearson 法相关检验显示，ADH5 mRNA 与FUNDC1 mRNA 在NSCLC 组织的表达呈显著负相关（r=-0.869，P=0.006）。年龄＜ 55 岁、TNM 分期III 期、低分化、并发淋巴结转移的NSCLC 组织中ADH5 mRNA 表达低于年龄≥ 55 岁、TNM 分期Ⅰ / Ⅱ期、高/ 中分化、无淋巴结转移（t=1.866 ～ 6.087）；低分化、并发淋巴结转移的NSCLC组织中FUNDC1 mRNA 表达高于高/ 中分化、无淋巴结转移（t=4.652，2.787），差异具有统计学意义（均P<0.05）。Kaplan-Meier 生存分析显示，ADH5 高表达组的累积总生存率（66.99%）显著高于ADH5 低表达组（54.15%），而FUNDC1 低表达组累积总生存率（69.47%）显著高于FUNDC1 高表达组（53.59%），差异具有统计学意义（LogRankχ2=5.760，5.165，P=0.016，0.023）。结论 在NSCLC 的患者肿瘤组织中ADH5 mRNA 呈低表达，FUNDC1 mRNA呈高表达，两者可能共同参与NSCLC 发生及转移，有望成为诊疗及预后预测的参考指标。
Abstract:
Objective To investigate the expression of alcohol dehydrogenase 5 (ADH5) mRNA and FUN14 domain containing 1 (FUNDC1) mRNA in non-small cell lung cancer (NSCLC) tissues and their relationship with clinical pathological characteristics and prognosis. Methods Collected clinical data of 332 patients who received treatment and non-small cell lung cancer(NSCLC) diagnosed through postoperative puthology at Xinjiang Uygur Autonomous Region People’s Hospital from July 2019 to July 2021. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression of ADH5 mRNA and FUNDC1 mRNA in NSCLC tissues and corresponding adjacent tissues (>5cm from the edge of the cancer tissue), and the expression differences and their correlation with the clinical and pathological characteristics of NSCLC patients were analyzed by t-test. Pearson rank correlation analysis was used to investigate the correlation between ADH5 mRNA and FUNDC1 mRNA. Kaplan-Meier method was used to analyze the relationship between the expression of ADH5 mRNA and FUNDC1 mRNA and the prognosis of NSCLC patients. Results The results of qRT-PCR showed that the expression level of ADH5 mRNA（0.56±0.30） in NSCLC tissues was significantly lower than that in paracancer normal tissues（1.03±0.50），and the expression level of FUNDC1 mRNA（2.91±1.02）was significantly higher than that in paracancer normal tissues（1.20±0.83），and the differences were statistically significant (t=14.687，23.694，all P<0.05). Correlation test by Pearson method showed that the expression of ADH5 mRNA and FUNDC1 mRNA in NSCLC tissues was significantly negatively correlated (r=-0.869, P=0.006). The expression of ADH5 mRNA in NSCLC tissues with age<55 years, TNM stage III，low differentiation and concurrent lymph node metastasis was lower than that in NSCLC tissues with age ≥ 55 years，TNM stage I/II，high/moderate differentiation and no lymph node metastasis (t=1.866 ～ 6.087)，the expression of FUNDC1 mRNA in NSCLC tissues with low differentiation and concurrent lymph node metastasis was higher than that in NSCLC tissues with high/moderate differentiation and no lymph node metastasis (t=4.652, 2.787), and the differences were statistically significant (all P<0.05). Kaplan-Meier survival analysis showed that the cumulative overall survival rate of the high ADH5 mRNA expression group (66.99%）was significantly higher than that of the low ADH5 mRNA expression group（54.15%）. The cumulative overall survival rate of low FUNDC1 mRNA expression group(69.47%）was significantly higher than that of high FUNDC1 mRNA expression group （53.59%) and the differences were statistically significant (Log Rankχ2=5.760, 5.165, P=0.016, 0.023). Conclusion Low expression of ADH5 mRNA and high expression of FUNDC1mRNA in tumor tissues of patients with NSCLC may be involved in the occurrence and metastasis of NSCLC, which is expected to become a reference index for diagnosis, treatment and prognosis prediction.

参考文献/References:

[1] 邱海平, 谢晓平, 陈天庆.1990 ~ 2019 年中国肺癌发病死亡趋势分析及年龄- 时期- 队列模型[J]. 中国癌症防治杂志,2023,15(5):537-542. QIU Haiping, XIE Xiaoping, CHEN Tianqing. A trend analysis of the incidence and mortality of lung cancer and an age-period-cohort model in China,1990-2019 [J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(5): 537-542.
[2] MITHOOWANI H, FEBBRARO M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology[J]. Current Oncology, 2022, 29(3): 1828-1839.
[3] ALDUAIS Y, ZHANG Haijun, FAN Fan, et al. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment[J]. Medicine(Baltimore), 2023, 102(8): e32899.
[4] 伍义文, 曹健斌, 黄维佳, 等.m6A 甲基转移酶METTL3介导miR-127 调控非小细胞肺癌细胞系自噬的机制研究[J]. 现代检验医学杂志,2022,37(2):12-16, 32. WU Yiwen, CAO Jianbin, HUANG Weijia, et al. Mechanism of M6A methyltransferase METTL3 mediates miR-127 to regulate autophagy in nonsmall cell lung cancer cell lines [J]. Journal of Modern Laboratory Medicine, 2022, 37(2): 12-16, 32.
[5] 骆慧, 于月, 廖照辉, 等. 线粒体自噬的信号通路及其在肿瘤中的研究进展[J]. 临床肿瘤学杂志,2022,27(7):661-668. LUO Hui, YU Yue, LIAO Zhaohui, et al. Progress on the signal pathway of mitochondrial autophagy and its application in tumor [J]. Chinese Clinical Oncology, 2022, 27(7): 661-668.
[6] PONNERI BABUHARISANKAR A, KUO Chengliang, CHOU Hanyu, et al. Mitochondrial lon-induced mitophagy benefits hypoxic resistance via Ca2+-dependent FUNDC1 phosphorylation at the ER-mitochondria interface[J]. Cell Death & Disease, 2023, 14(3): 199.
[7] JIAO Lijin, SU Lingyan, LIU Qianjin, et al. GSNOR deficiency attenuates MPTP-induced neurotoxicity and autophagy by facilitating CDK5 S-nitrosation in a mouse model of Parkinson’s disease [J]. Free Radical Biology and Medicine, 2022, 189:111-121.
[8] ZHANG Weilin. The mitophagy receptor FUN14 domain-containing 1 (FUNDC1): a promising biomarker and potential therapeutic target of human diseases[J]. Genes Diseases, 2021, 8(5): 640-654.
[9] SUN Junhao, ZHANG Xinyu, WU Fan, et al. Elevated ADH5 expression suggested better prognosis in kidney renal clear cell carcinoma (KIRC) and related to immunity through single-cell and bulk RNAsequencing[J]. BMC Urology, 2024, 24(1): 84.
[10] 赫捷, 李霓, 陈万青, 等. 中国肺癌筛查与早诊早治指南(2021, 北京) [J]. 中国肿瘤,2021,30(2):81-111. HE Jie, LI Ni, CHEN Wanqing, et al. China guideline for the screening and early detection of lung cancer(2021, Beijing)[J]. China Cancer, 2021, 30(2): 81-111.
[11] 王泽洲, 郑莹.1990 年至2020 年间全球及我国肺癌的发病流行趋势及防控措施[J]. 诊断学理论与实践,2023,22(1):1-7. WANG Zezhou, ZHENG Ying. Lung cancer worldwide and in China from 1990 to 2020:prevalence and prevention measures[J].Journal of Diagnostics Concepts & Practice, 2023, 22(1): 1-7.
[12] CHEN Peixin, LIU Yunhuan, WEN Yaokai, et al. Nonsmall cell lung cancer in China[J]. Cancer Communications(London, England), 2022, 42(10): 937-970.
[13] JONNA S, SUBRAMANIAM D S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J]. Discovery Medicine, 2019, 27(148): 167-170.
[14] PENNELL N A, ARCILA M E, GANDARA D R, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices [J]. American Society of Clinical Oncology Educational Book, 2019, 39: 531-542.
[15] ZHAO Jie, WEI Qian, GU Xinrong, et al. Alcohol dehydrogenase 5 of Helicoverpa armigera interacts with the CYP6B6 promoter in response to 2-tridecanone[J].Insect Science, 2020, 27(5): 1053-1066.
[16] SHU Feng, XIAO Han, LI Qiunuo, et al. Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 32.
[17] 罗以楠. 线粒体自噬中受体蛋白FUNDC1 研究进展[J]. 医学研究生学报,2020,33(5):537-542. LUO Yinan. Research progress of receptor protein FUNDC1 in mitophagy[J]. Journal of Medical Postgraduates, 2020, 33(5): 537-542.
[18] LI Jie, AGARWAL E, BERTOLINI I, et al. The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells[J].Science Signaling, 2020, 13(642): eaaz8240.
[19] LARRICK J W, MENDELSOHN A R. Regulation of S-nitrosylation in aging and senescence[J].Rejuvenation Research, 2019, 22(2): 171-174.
[20] 王玉秀, 陈燏, 龚道辉, 等. 基于TCGA 数据库及临床病理学探索非小细胞肺癌中FUNDC1 的表达及预后意义[J]. 肿瘤防治研究,2022,49(4):322-327. WANG Yuxiu, CHEN Yu, GONG Daohui, et al. Evaluation of expression and prognostic significance of FUNDC1 protein in non-small cell lung cancer based on TCGA database and clinicopathology[J]. Cancer Research on Prevention and Treatment, 2022, 49(4): 322-327.
[21] WANG Peng, ZHANG Linbo, HUANG Chunxia, et al. Distinct prognostic values of alcohol dehydrogenase family members for non-small cell lung cancer [J].Medical Science Monitor, 2018, 24: LBR3578-3590.
[22] MA Kaili, ZHANG Zhi, CHANG Rui, et al. Dynamic PGAM5 multimers dephosphorylate BCL-xL or FUNDC1 to regulate mitochondrial and cellular fate[J].Cell Death and Differentiation, 2020, 27(3): 1036-1051.
[23] LIANG Yiran, WANG Yajie, ZHANG Yan, et al. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-κB signaling pathway in breast cancer[J]. Cell Death & Disease, 2023, 14(7): 434.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(02):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(02):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(02):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(02):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(02):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目：新疆维吾尔自治区自然科学基金（2020D01A112），新疆维吾尔自治区人民医院项目（20180317）。
作者简介：杜亮（1987-），男，硕士研究生，主治医师，研究方向：肺部肿瘤，E-mail：Duadu957@163.com。
通讯作者：马金山（1965-），男，硕士研究生，主任医师，研究方向：肺部肿瘤，E-mail：xjmajinshan@sina.com。
更新日期/Last Update: 2025-03-15